(299 days)
No
The device description focuses on the chemical composition and physical properties of bone cement, with no mention of software, algorithms, or data processing that would indicate the use of AI/ML.
Yes
The device is indicated for the treatment of pathological fractures of the vertebral body, which is a therapeutic purpose. It is also used in medical procedures like vertebroplasty or balloon kyphoplasty.
No
Explanation: This device is a bone cement used for treating pathological fractures, not for diagnosing them. It is a therapeutic device.
No
The device description clearly states that V-STEADY and V-FAST are polymethylmethacrylate (PMMA) based bone cements, which are physical materials used in surgical procedures. The summary details the chemical composition and physical properties of the cements, indicating they are hardware components, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for treating pathological fractures of the vertebral body using vertebroplasty or balloon kyphoplasty procedures. This is a surgical/interventional procedure performed directly on the patient's body.
- Device Description: The device is a bone cement, a material implanted into the body to stabilize fractures. It's a physical substance used in a medical procedure, not a reagent or instrument used to test samples taken from the body.
- Lack of IVD Characteristics: There is no mention of analyzing samples (blood, urine, tissue, etc.), detecting biomarkers, or providing diagnostic information based on in vitro testing.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This bone cement does not fit that description.
N/A
Intended Use / Indications for Use
V-STEADY and V-FAST bone cements are indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a vertebroplasty or balloon kyphoplasty procedure.
Product codes (comma separated list FDA assigned to the subject device)
LOD, NDN
Device Description
V-STEADY and V-FAST are polymethylmethacrylate (PMMA) based bone cements formulated to perform percutaneous vertebral augmentation procedures, such as vertebroplasty . Bone cements are self-curing systems consisting of liquid and powder components:
- the powder component is constituted of PMMA beads shaped particles containing the initiator benzoyl peroxide required for starting initiating the cement curing. The radiopacifier agent, zirconium dioxide, is necessary for the cement visibility under radiographs but it does not take part of the curing process (radical polymerization).
- The liquid component comprises the monomer, methylmethacrylate (MMA); dimethyl-para-toluidine (DMPT) as polymerization accelerator and hydroquinone (HQ) as stabilizer to prevent polymerization of the liquid during storage.
The specific content of PMMA and benzoyl peroxide is slightly different between the two cements conferring upon them specific properties. V-STEADY bone cement has an immediate development of viscosity and thus it is a high viscosity cement that maintains its properties throughout the useful working time. The V-FAST has a low initial viscosity and a long working time allowing to work extremely carefully when a good time margin before polymerization is required. Both the liquid and powder components are supplied sterile-filtered monomer component is supplied in an amber glass ampoule (10 ml) and comes in a blister pack sterilized by ethylene oxide. The polymer powder component is supplied in a double sterile packaging.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
vertebral body
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following performance data are provided in support of the substantial equivalence determination:
● Biocompatibility: As recommended by the FDA's Guidance "Use of International Standard ISO-10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing' (Replaces #G87-1 #8294) (blue book memo), the subject devices comply with ISO 10993.
. Sterilization: The sterilization process (including both the ethylene oxide method (powder component and aseptically processed, filled glass vials) as well as the filter-sterilization (liquid component)) has been validated and the sterility of the subject devices has been verified according to ISO 11135:2014, ISO 11138-1:2006, ISO 10993-7:2009, ISO 14161:2009, ISO 14937:2009, ISO 11737-1:2006, ISO 11737-2:2009, ISO 13408-1:2008 and ISO 13408-2:2003.
● Material, Mechanical and Performance Characterization: A comprehensive set of performance testing was conducted to characterize V-STEADY and V-FAST bone cements as compared to the predicate, according to the FDA's Guide "Class II Special Controls Guidance Document: polymethylmethacrylate (PMMA) Bone Cement; Guidance for Industry and FDA".
Results show comparable performances to the predicate and reference devices, and are in compliance with ASTM F451-08, ISO 5833:2002, ASTM F2118-14, ASTM D2990-09, ASTM D638, and ASTM E399-12.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3027 Polymethylmethacrylate (PMMA) bone cement.
(a)
Identification. Polymethylmethacrylate (PMMA) bone cement is a device intended to be implanted that is made from methylmethacrylate, polymethylmethacrylate, esters of methacrylic acid, or copolymers containing polymethylmethacrylate and polystyrene. The device is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of polymer or metallic prosthetic implants to living bone.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Polymethylmethacrylate (PMMA) Bone Cement.”
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized graphic of three human profiles facing to the right, stacked one on top of the other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 14, 2015
G21 S.r.l. Mr. Maurizio Foroni President Via Sandro Pertini, 8 41039 San Possidonio (MO) ITALY
Re: K150408
Trade/Device Name: V-STEADY and V-FAST Regulation Number: 21 CFR 888.3027 Regulation Name: Polymethylmethacrylate (PMMA) bone cement Regulatory Class: Class II Product Code: LOD, NDN Dated: October 30, 2015 Received: November 2, 2015
Dear Mr. Foroni:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
| DEPARTMENT OF HEALTH AND HUMAN SERVICES | Form Approved: OMB No. 0910-0120 |
|---|---|
| Food and Drug Administration | Expiration Date: January 31, 2017 |
| Indications for Use | See PRA Statement below. |
| 510(k) Number (if known) | |
| K150408 |
Device Name V-STEADY and V-FAST
Indications for Use (Describe)
V-STEADY and V-FAST bone cements are indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a vertebroplasty or balloon kyphoplasty procedure.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (1/14)
3
510(k) Summary
This 510(k) Summary has being submitted in accordance with the requirements of 21 CFR 807.92 and the FDA's guidance The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notification [510(k)].
| 1. General Information | |
|---|---|
| Submitter: | G21 srl |
| via S. Pertini, 8 | |
| 41039 San Possidonio (MO)- ITALY | |
| Phone: +39 0535 30312 | |
| Fax: +39 0535 417332 | |
| Contact Person in Italy: | Maurizio Foroni |
| Via S. Pertini, 8 | |
| 41039 San Possidonio (MO)-ITALY | |
| Phone: +39 0535 30312 | |
| Fax: +39 0535 417332 | |
| Email: info@g-21.it | |
| Contact Person in USA: | M Squared Associates, Inc. |
| 575 8th Avenue, Suite 1212 | |
| New York, NY 10018 | |
| Marie Marlow | |
| Telephone 703-562-9800 x201 | |
| Deborah Lavoie Grayeski | |
| Telephone 703-562-9800 x250 | |
| Email: | |
| dgrayeski@msquaredassociates.com | |
| Summary Preparation Date: | December 4, 2015 |
| 2. Device | |
| Device Name: | V-STEADY and V-FAST |
| Classification name: | Polymethylmethacrylate (PMMA) |
| bone cement | |
| Product Code: | LOD |
| NDN | |
| Regulation number: | 888.3027 |
| Class: | II |
4
3. Predicate Device
The subject devices family (V-STEADY and V-FAST) is substantially equivalent to the following legally marketed predicate device:
| Applicant | Device name | 510(k) Number | Product code |
|---|---|---|---|
| HERAEUS KULZER GMBH | OSTEOPAL®V | K050085 | LOD |
| NDN |
Additionally, reference devices, as listed below, were selected only to provide scientific or technical information to support the subject devices.
| Applicant | Device name | 510(k) Number | Product code |
|---|---|---|---|
| TECRES SPA | MENDEC SPINE | K042415 | LOD |
| NDN | |||
| STRYKER CORPORATION | STRYKER VERTAPLEX HV | K091606 | LOD |
| NDN |
4. Device Description
V-STEADY and V-FAST are polymethylmethacrylate (PMMA) based bone cements formulated to perform percutaneous vertebral augmentation procedures, such as vertebroplasty . Bone cements are self-curing systems consisting of liquid and powder components:
- the powder component is constituted of PMMA beads shaped particles containing the initiator benzoyl peroxide required for starting initiating the cement curing. The radiopacifier agent, zirconium dioxide, is necessary for the cement visibility under radiographs but it does not take part of the curing process (radical polymerization).
- The liquid component comprises the monomer, methylmethacrylate (MMA); dimethyl-para-toluidine (DMPT) as polymerization accelerator and hydroquinone (HQ) as stabilizer to prevent polymerization of the liquid during storage.
The specific content of PMMA and benzoyl peroxide is slightly different between the two cements conferring upon them specific properties. V-STEADY bone cement has an immediate development of viscosity and thus it is a high viscosity cement that maintains its properties throughout the useful working time. The V-FAST has a low initial viscosity and a long working time allowing to work extremely carefully when a good time margin before polymerization is required. Both the liquid and powder components are supplied sterile-filtered monomer component is supplied in an amber glass ampoule (10 ml) and comes in a blister pack sterilized by ethylene oxide. The polymer powder component is supplied in a double sterile packaging.
5
G-21 S.R.L. 510(K) PREMARKET NOTIFICATION
The sterilization process is ethylene oxide and it has been properly validated.
Preparation and application procedures of the subject devices are detailed within the labeling as Mixing Phase, Waiting Phase, Application Phase, Setting/Hardening Phase.
5. Indications for use
V-STEADY and V-FAST bone cements are indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a vertebroplasty or balloon kyphoplasty procedure.
6. Comparison of technological characteristics with the predicate devices.
V-STEADY and V-FAST bone cements share many of the same technological characteristics compared to the predicate device, OSTEOPAL V, including fundamental features such as chemical formulation, packaging configuration, sterilization methods, mechanical performances and handling phases. There are however few differences in shelf life, presence of coloured pigment in the predicate only, as detailed in the table below:
| G21 device family | Predicate Device | ||
|---|---|---|---|
| V-STEADY | V-FAST | OSTEOPAL V (K050085) | |
| Chemical composition | |||
| Powder | |||
| Component | Polymethylmethacrylate (PMMA) | ||
| Zirconium Dioxide (ZrO2) | |||
| Benzoyl Peroxide (BPO) | Polymethylmethacrylate | ||
| (PMMA) | |||
| Zirconium Dioxide (ZrO2) | |||
| Benzoyl Peroxide (BPO) | Polymethylmethacrylate | ||
| (PMMA) | |||
| Zirconium Dioxide (ZrO2) | |||
| Benzoyl Peroxide (BPO) | |||
| Liquid | |||
| Component | Metylmethacrylate (MMA) | ||
| N,N-dymethyl-p-toluidine (DMPT) | |||
| Hydroquinone (HQ) | Metylmethacrylate (MMA) | ||
| N,N-dymethyl-p-toluidine | |||
| (DMPT) | |||
| Hydroquinone (HQ) | Metylmethacrylate (MMA) | ||
| N,N-dymethyl-p-toluidine | |||
| (DMPT) | |||
| Hydroquinone (HQ) | |||
| Other | |||
| constituents | None | None | Chlorophyll |
| Shelf Life | 1 year | 1 year | 5 years |
6
7. Performance Data
The following performance data are provided in support of the substantial equivalence determination:
● Biocompatibility
As recommended by the FDA's Guidance "Use of International Standard ISO-10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing' (Replaces #G87-1 #8294) (blue book memo), the subject devices comply with ISO 10993.
. Sterilization
The sterilization process (including both the ethylene oxide method (powder component and aseptically processed, filled glass vials) as well as the filter-sterilization (liquid component)) has been validated and the sterility of the subject devices has been verified according to ISO 11135:2014, ISO 11138-1:2006, ISO 10993-7:2009, ISO 14161:2009, ISO 14937:2009, ISO 11737-1:2006, ISO 11737-2:2009, ISO 13408-1:2008 and ISO 13408-2:2003.
● Material, Mechanical and Performance Characterization
A comprehensive set of performance testing was conducted to characterize V-STEADY and V-FAST bone cements as compared to the predicate, according to the FDA's Guide "Class II Special Controls Guidance Document: polymethylmethacrylate (PMMA) Bone Cement; Guidance for Industry and FDA".
Results show comparable performances to the predicate and reference devices, and are in compliance with ASTM F451-08, ISO 5833:2002, ASTM F2118-14, ASTM D2990-09, ASTM D638, and ASTM E399-12.
8. Conclusions
The subject device family has the same classification and intended use as the predicate device. Also, several tests were conducted as recommended by the FDA's Guide "Class II Special Controls Guidance Document: polymethylmethacrylate (PMMA) Bone Cement; Guidance for Industry and FDA" to address safety and performance characteristics (e.g. biocompatibility, sterilization, shelf life, chemical and mechanical tests). The obtained results demonstrate that the subject devices perform as intended in the specific use conditions and comply with applicable standards, similarly to the predicate device. Thus, on the basis of evidence discussed above, the V-STEADY and V-FAST can be deemed substantially equivalent to the predicate device K050085.